Moderation of the daily dose of HRT: benefits for patients (Q33830907)

29 July 2017

title

Moderation of the daily dose of HRT: benefits for patients (English)

1 reference

Hormone Replacement Therapy

29 July 2017

main subject

1 reference

Schneider HP

1

1 reference

29 July 2017

Gallagher JC

series ordinal

2

1 reference

29 July 2017

publication date

1 November 1999

1 reference

29 July 2017

1 reference

29 July 2017

volume

33 Suppl 1

1 reference

29 July 2017

page(s)

S25-9

1 reference

Postmenopausal hormone therapy and mortality.

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2899%2900060-2

7 January 2021

Hormone therapy to prevent disease and prolong life in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2899%2900060-2

7 January 2021

Can we improve compliance with long-term HRT?

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2899%2900060-2

7 January 2021

Estrogen replacement therapy: what the future holds

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2899%2900060-2

7 January 2021

The physiology and measurement of hot flushes

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2899%2900060-2

7 January 2021

Risk factors associated with women's compliance with estrogen replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2899%2900060-2

7 January 2021

Comparison of two estradiol transdermal systems (Oesclim 50 and Estraderm TTS 50). I. Tolerability, adhesion and efficacy.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2899%2900060-2

7 January 2021

Efficacy and safety of low, standard, and high dosages of an estradiol transdermal system (Esclim) compared with placebo on vasomotor symptoms in highly symptomatic menopausal patients. The Esclim Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2899%2900060-2

7 January 2021

Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Estratab/Osteoporosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2899%2900060-2

7 January 2021

Postmenopausal Estrogen and Progestin Use and the Risk of Cardiovascular Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2899%2900060-2

7 January 2021

Matrix delivery transdermal 17beta-estradiol for the prevention of bone loss in postmenopausal women. The International Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5122%2899%2900060-2

7 January 2021

10.1016/S0378-5122(99)00060-2

Identifiers

DOI

1 reference

29 July 2017

1 reference